Hospira on the Ball: Paying Attention to FDA Complaints Under New CEO
By
Cole Werble / Email the Author / The RPM Report November 2011, Vol. 7, No. 11
Street Smarts / Word Count: 3763 / Article # 2011500142
Executive Summary
Hospira’s new CEO Mike Ball was charting a global expansion and touting a move into biosimilars. Then the lingering quality control discussions with FDA caught up with the company and forced their way to the top of his agenda. That may be an important step for the company in the long-term.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.